Q32 Bio (QTTB) announced additional results from Part A of its SIGNAL-AA Phase 2a clinical trial of bempikibart in patients with alopecia areata, AA, at the 2025 American Academy of Dermatology ...
Feb. 10, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis, today ...
WALTHAM, Mass., Feb. 4, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback